Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

News

Biognosys schließt Wiederverkaufsvertrag für Proteomik-Software „Spectronaut“ mit führendem Anbieter von Massenspektrometriesystemen ab
Biognosys schließt Wiederverkaufsvertrag für Proteomik-Software „Spectronaut“ mit führendem Anbieter von Massenspektrometriesystemen ab
  • Spectronaut® von Biognosys, die führende herstellerunabhängige Software für die DIA-Proteomik, ist jetzt direkt von Thermo Fisher Scientific im Rahmen einer Wiederverkaufsvereinbarung erhältlich
CARBIOS und FCC Environment planen gemeinsam die Errichtung einer PET-Biorecycling-Anlage auf Basis der lizenzierten Technologie von CARBIOS in Großbritannien
CARBIOS und FCC Environment planen gemeinsam die Errichtung einer PET-Biorecycling-Anlage auf Basis der lizenzierten Technologie von CARBIOS in Großbritannien

Clermont-Ferrand (Frankreich) und Doncaster (England), Dienstag, 06. August (06:45 Uhr MESZ). CARBIOS, (Euronext Growth Paris: ALCRB), ein Pionier in der Entwicklung und Industrialisierung

Biognosys und Alamar Biosciences schließen strategische Partnerschaft im Bereich Proteomik zur Förderung der Biopharma- und Präzisionsmedizin-Forschung: https://ml-eu.globenewswire.com/Resource/Download/a3c7222c-847f-45e7-b715-0be59ad88eb0/image2.png
Biognosys und Alamar Biosciences schließen strategische Partnerschaft im Bereich Proteomik zur Förderung der Biopharma- und Präzisionsmedizin-Forschung
  • Strategische Partnerschaft erweitert die Dienstleistungen von Biognosys um die NULISA-Assays von Alamar sowie die gemeinsame wissenschaftliche Forschung im Bereich der biofluidbasierten Proteomik
Biognosys erweitert US-Präsenz mit neuer CRO-Einrichtung für Proteomik in Massachusetts
Biognosys erweitert US-Präsenz mit neuer CRO-Einrichtung für Proteomik in Massachusetts
  • Die neue CRO-Einrichtung für Proteomik-Dienstleistungen in Newton, Massachusetts, gewährleistet eine größere Nähe zu den US-Kunden
  • Das Kompetenzzentrum für Proteomik-Innovationen am Hauptsitz von
shareribs.com - Auftragseingang bei Windkraftanlagen steigt auf Rekordhoch
shareribs.com - Auftragseingang bei Windkraftanlagen steigt auf Rekordhoch
shareribs.com - New York 04.09.2023 - Der Ausbau erneuerbarer Energiekapazitäten nimmt weltweit zu. Insbesondere bei der Windenergie bleibt das Wachstum jedoch hinter dem Bedarf zurück. Dennoch
Colonial Increases Its Stake in SFL
Colonial Increases Its Stake in SFL


The Colonial Group has approved a simplification of the shareholding structure of its subsidiary SFL which reinforces its Real Estate exposure in Paris and consists in:




  • a contribution by

Siemens Gamesa: Aktie, flieg mit dem Wind
Siemens Gamesa: Aktie, flieg mit dem Wind

Siemens Gamesa Renewable Energy (WKN: A0B5Z8), kurz SGRE oder Siemens Gamesa, ist ein börsennotierter, international tätiger Hersteller von Windkraftanlagen mit Hauptsitz in Zamudio bei Bilbao

Nordex: Sieht das etwa wie ein Aufstieg aus? Zocker-Trading-Chance!
Nordex: Sieht das etwa wie ein Aufstieg aus? Zocker-Trading-Chance!
Unser letzter Beitrag über Nordex liegt schon etwa 2 Wochen zurück. Der Artikel wurde dem Titel: „Nordex: Schrecken ohne Ende oder ist da etwas Licht am Ende des Tunnels?“ veröffentlicht. Im Text....
Acerinox: zuversichtlich ins Jahr 2017!
Acerinox: zuversichtlich ins Jahr 2017!
Liebe Leser, Nach einem durchwachsenen 1. Halbjahr, das von schwachen Basispreisen und dem Abbau der Vorräte seitens der Kunden geprägt war, hat sich die Situation im 3. Quartal verbessert. Viele....
Banco Popular tauscht Vorstandschef aus
Banco Popular tauscht Vorstandschef aus
Liebe Leser, das krisengeschüttelte spanische Geldhaus Banco Popular bekommt einen neuen Vorstandschef. Nach Angaben des sechstgrößten Finanzinstituts Spaniens wird Pedro Larena ab September die Geschicke
Where Will Sirius XM Stock Be in 5 Years?: https://g.foolcdn.com/editorial/images/790827/senior-investor-watching-market-data-1289228163.jpg
Where Will Sirius XM Stock Be in 5 Years?

With shares down around 60% over the last five years, Sirius XM (NASDAQ: SIRI) has battered its long-term investors. And it's no surprise management turned to a 1-for-10 reverse stock split to keep

Why Intuitive Machines Popped, but Rocket Lab and AST SpaceMobile Stocks Dropped Today: https://g.foolcdn.com/editorial/images/787880/risk-danger-dial-high.jpg
Why Intuitive Machines Popped, but Rocket Lab and AST SpaceMobile Stocks Dropped Today

Volatility ran amok among space stocks Tuesday. Shares of lunar explorer Intuitive Machines (NASDAQ: LUNR) rocketed 35.6% through 3 p.m. ET, but rocket maker Rocket Lab (NASDAQ: RKLB) and satcom

Why AST SpaceMobile Stock Popped, Then Dropped: https://g.foolcdn.com/editorial/images/786144/rocket-with-dollar-sign-payload-launches-to-the-moon.jpg
Why AST SpaceMobile Stock Popped, Then Dropped

Yesterday's stock market sell-off hurt a lot of stocks, but AST SpaceMobile (NASDAQ: ASTS) wasn't one of them. Defying the market rout, shares of the start-up space company promising satellite

Indra Signs a Framework Agreement to Equip Airports in the United States With Technology for the Surveillance and Monitoring of Surface Aircraft: https://mms.businesswire.com/media/20240708875763/en/2179009/5/Aeropuerto_Dallas_Love_Field.jpg
Indra Signs a Framework Agreement to Equip Airports in the United States With Technology for the Surveillance and Monitoring of Surface Aircraft


Indra will supply Surface Awareness Initiative (SAI) systems for the United States Federal Aviation Administration (FAA), the civil aviation authority that manages the country’s air traffic. The

Almirall Launches Act4Impact – its Updated Sustainability Strategy Setting Ambitious Targets for 2030: https://mms.businesswire.com/media/20240702917901/en/2175827/5/Almirall_photovoltaic_installation_HQ_Barcelona.jpg
Almirall Launches Act4Impact – its Updated Sustainability Strategy Setting Ambitious Targets for 2030


Almirall S.A. (BME: ALM), a global pharmaceutical company dedicated to medical dermatology, launched its new sustainability strategy Act4Impact 2030 today. The updated strategy aims at transforming

Almirall Delivers Strong Start of 2024 – Q1 Net Sales Growth of 6.6% Overall and 18% in the European Dermatology Business, Driven by Biologics and Solid Performance of Broad Product Portfolio: https://mms.businesswire.com/media/20240512974045/en/2128406/5/Almirall_fachada_R%26D_St_Feliu.jpg
Almirall Delivers Strong Start of 2024 – Q1 Net Sales Growth of 6.6% Overall and 18% in the European Dermatology Business, Driven by Biologics and Solid Performance of Broad Product Portfolio


Almirall, S.A. (ALM) a global biopharmaceutical company based in Barcelona, today announced its financial results from the first quarter 2024. Almirall delivered strong sales growth in the first

Why Comcast Stock Dropped Today: https://g.foolcdn.com/editorial/images/769342/black-and-white-drawing-of-an-electric-plug-and-a-connector.jpg
Why Comcast Stock Dropped Today

Shares of cable TV and internet provider Comcast (NASDAQ: CMCSA) stock slipped 2.3%, falling exactly $1 in share price through 12:30 p.m. ET Thursday.

The stock appears to be reacting to breaking

Why AST SpaceMobile Stock Keeps Rocketing Higher: https://g.foolcdn.com/editorial/images/769184/1-arrow-angles-up-on-a-green-stock-chart.jpg
Why AST SpaceMobile Stock Keeps Rocketing Higher

The stock of AST SpaceMobile (NASDAQ: ASTS) popped again on Wednesday, after the satellite communications company announced on Tuesday that it has updated its filings with the International

Almirall Licenses an Anti-IL-21 Monoclonal Antibody From Novo Nordisk to Develop It as a First-in-Class Agent in Dermatology: https://mms.businesswire.com/media/20240218250953/en/2037911/5/Almirall_RandD_2.jpg
Almirall Licenses an Anti-IL-21 Monoclonal Antibody From Novo Nordisk to Develop It as a First-in-Class Agent in Dermatology


Almirall S.A. (BME: ALM), a global pharmaceutical company dedicated to medical dermatology, announced today that it has entered into an exclusive license agreement with Novo Nordisk for rights to

Almirall continues its progress to leadership in Medical Dermatology driven by strong growth in the European Dermatology business: https://mms.businesswire.com/media/20240218334003/en/1647007/5/Almirall_HQ_in_Barcelona.jpg
Almirall continues its progress to leadership in Medical Dermatology driven by strong growth in the European Dermatology business


Almirall, S.A. (ALM) a global biopharmaceutical company based in Barcelona, today announced its full-year 2023 financial results.


This press release features multimedia. View the full release

Why Is SpaceX Partnering With John Deere?: https://g.foolcdn.com/editorial/images/763415/harvester-and-loading-truck-working-in-a-cornfield-viewed-from-above.jpg
Why Is SpaceX Partnering With John Deere?

SpaceX Starlink is a success.

Going from a concept in 2015 to beta service in 2021, SpaceX's plan to build a network of fast internet communications satellites has grown from 0 to 10,000 to 2.2

Almirall Initiates First Phase I Clinical Study of ALM223, an Interleukin 2 Mutant Fusion Protein for Autoimmune Diseases: https://mms.businesswire.com/media/20231221296013/en/1647007/5/Almirall_HQ_in_Barcelona.jpg
Almirall Initiates First Phase I Clinical Study of ALM223, an Interleukin 2 Mutant Fusion Protein for Autoimmune Diseases


Almirall S.A. (BME: ALM), a global pharmaceutical company focused on medical dermatology, today announced the initiation of the phase I study evaluating the safety, pharmacokinetics,

Almirall: Up to 73% of Atopic Dermatitis Patients Taking Lebrikizumab Had Improved or Cleared Skin on Face or Hands in New Analysis: https://mms.businesswire.com/media/20230501005338/en/1647007/5/Almirall_HQ_in_Barcelona.jpg
Almirall: Up to 73% of Atopic Dermatitis Patients Taking Lebrikizumab Had Improved or Cleared Skin on Face or Hands in New Analysis


Almirall S.A. (ALM) today announced results from a new secondary analysis from the Phase 3 clinical development program which showed patients receiving lebrikizumab who were assessed at 16 weeks

Almirall joins FACILITATE, a patient-driven Innovative Medicines Initiative (IMI) project to enable the use of clinical trial data by study participants: https://mms.businesswire.com/media/20221127005124/en/1647007/5/Almirall_HQ_in_Barcelona.jpg
Almirall joins FACILITATE, a patient-driven Innovative Medicines Initiative (IMI) project to enable the use of clinical trial data by study participants


Almirall, S.A. (ALM), a global biopharmaceutical company focused on skin health, today announced that it is participating in FACILITATE, (FrAmework for ClInicaL trIal participants’ daTA

Almirall’s H1 2024 Results: Almirall Delivers Strong Performance in the First Half of 2024, Achieving Net Sales Growth of 6.7% Driven by Its European Dermatology Business and Accelerating Biologics Sales: https://mms.businesswire.com/media/20221109006035/en/1631769/5/ALM_AW_LOGO_Tagline_MV_Positive_RGB_%281%29.jpg
Almirall’s H1 2024 Results: Almirall Delivers Strong Performance in the First Half of 2024, Achieving Net Sales Growth of 6.7% Driven by Its European Dermatology Business and Accelerating Biologics Sales


Almirall, S.A. (ALM) a global biopharmaceutical company based in Barcelona, today announced its financial results from the first half of 2024. Almirall continued to deliver strong sales growth in